During the 1990s, Lundbeck opened subsidiary operations in 20 countries including Canada. Based on the world-wide introduction of Citalopram an antidepressant known as a selective serotonin reuptake inhibitor (SSRI), Lundbeck established Canadian operations to ensure the availability of Celexa® (citalopram) as it is known in Canada.
A dedicated group of employees began forging relationships with Canadian physicians building awareness of the company and two important products for the treatment of schizophrenia: Clopixol® and Fluanxol®, both used today. Celexa® (citalopram) received regulatory approval from Health Canada in 1999, confirming Lundbeck’s commitment in the Canadian market. Today 225 Canadians work at Lundbeck Canada.
Celexa® (citalopram) became the most successful antidepressant in Canadian history. After the generic version of citalopram entered the market, Lundbeck Canada introduced two new products: Cipralex® (escitalopram), a second generation SSRI, and Ebixa® (memantine), the first drug in a new therapeutic class for moderate to severe Alzheimer's disease. The company continues to lead Canadian-based clinical research activity focused on brain diseases as Canadian researchers conduct trials with Lundbeck products and pursue innovative treatments for Canadians.
Lundbeck Canada also made available Treanda® for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma and Trisenox for the treatment of acute promyelocytic leukemia, enabling Lundbeck Canada to create new partnerships with healthcare professionals in the field of oncology.